Perrigo (PRGO) Cash from Investing Activities (2013 - 2026)
Perrigo's (PRGO) quarterly Cash from Investing Activities came in at -$12.4 million in Q1 2026, up 51.75% year-on-year from -$8.2 million in Q1 2025, and up 49.39% on a QoQ basis from -$24.5 million in Q4 2025.
Perrigo (PRGO) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Cash from Investing Activities data on file, last reported at -$12.4 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 51.75% year-over-year to -$12.4 million in Q1 2026; TTM through Mar 2026 was -$62.1 million, a 181.07% decrease from a year earlier, with the FY2025 full-year figure at -$75.4 million, down 195.69% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$12.4 million, up from -$24.5 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for PRGO reached as high as $212.7 million in Q3 2024 and fell as low as -$2.0 billion in Q3 2022.
- Historically, Cash from Investing Activities has averaged -$120.3 million across 5 years, with a median of -$22.8 million in 2023.
- Across the five-year window, Cash from Investing Activities tumbled 8956.88% in 2022 and jumped 792.83% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$26.0 million in 2022, then gained by 12.31% to -$22.8 million in 2023, then slumped by 62.72% to -$37.1 million in 2024, then surged by 33.96% to -$24.5 million in 2025, then soared by 49.39% to -$12.4 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$12.4 million in Q1 2026, -$24.5 million in Q4 2025, and -$21.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.68 Bn | 30.74 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.34 Bn | 18.54 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Perrigo | 1.45 Bn | 1.09 Bn | 325.50 Mn | -12.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -12.40 Mn |
| Mar 28, 2026 | -12.40 Mn |
| Dec 31, 2025 | -24.50 Mn |
| Dec 31, 2025 | -24.50 Mn |
| Sep 27, 2025 | -21.40 Mn |
| Sep 27, 2025 | -21.40 Mn |
| Jun 28, 2025 | -3.80 Mn |
| Jun 28, 2025 | -3.80 Mn |
| Mar 29, 2025 | -25.70 Mn |
| Mar 29, 2025 | -25.70 Mn |
| Dec 31, 2024 | -37.10 Mn |
| Dec 31, 2024 | -37.10 Mn |
| Sep 28, 2024 | 212.70 Mn |
| Sep 28, 2024 | 212.70 Mn |
| Jun 29, 2024 | -73.30 Mn |
| Jun 29, 2024 | -73.30 Mn |
| Mar 30, 2024 | -23.50 Mn |
| Mar 30, 2024 | -23.50 Mn |
| Dec 31, 2023 | -22.80 Mn |
| Dec 31, 2023 | -22.80 Mn |